Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1

2015 ◽  
Vol 33 (6) ◽  
pp. 708-714 ◽  
Author(s):  
Naoshi Nishida ◽  
Mina Iwanishi ◽  
Tomohiro Minami ◽  
Hirokazu Chishina ◽  
Tadaaki Arizumi ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Triple Therapy ◽  
Virological Response ◽  
Rapid Decline ◽  
Hcv Rna ◽  
Rapid Virological Response ◽  
Virus Genotype ◽  
Early Viral Response ◽  
Triple Regimen ◽  
Detectable Serum

Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naïve cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral load during treatment. Methods: Forty-six CHC patients with HCV genotype 1b were treated with PEG-IFN/RBV/SMV triple therapy: 20 were naïve cases, 12 were relapsers and 14 were non-responders to prior PEG-IFN/RBV therapy. We evaluated rapid virological response (RVR), complete early virological response (EVR), viral clearance at the end of the treatment (EOT) and at 12 weeks after the EOT (SVR12). In addition, we quantified the serum HCV-RNA on the 1st day and the 7th day after initiating treatment. Results: Multivariate analysis revealed that response to prior treatment was identified as an independent factor for achieving SVR12 after triple therapy (p = 0.0005). The achievement of serum HCV-RNA <2 log10 IU/ml on day 7, RVR, EVR and EOT were associated with SVR12 (p = 0.0050, p = 0.0002, p = 0.0009 and p = 0.0002, respectively). Conclusions: Rapid decline of HCV is a predictive factor for the achievement of SVR12, even in antiviral triple therapy with PEG-IFN/RBV/SMV. An extended treatment period should be applied for patients who show detectable serum HCV-RNA at week 4.

scholarly journals Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Hiroshi Abe ◽  
Akihito Tsubota ◽  
Noritomo Shimada ◽  
Masanori Atsukawa ◽  
Keizo Kato ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Virological Response ◽  
Multivariate Logistic Regression Analysis ◽  
Hcv Rna ◽  
Rapid Virological Response ◽  
Related Factors ◽  
Genotype 1B ◽  
Predictors Of Response ◽  
Treatment Naïve ◽  
Intent To Treat

We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P= 7.38 × 10−4). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P= 2.47 × 10−5). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.

Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2

Hepatology ◽  
2008 ◽  
Vol 48 (1) ◽  
pp. 342-342 ◽  
Author(s):  
Chia‐Yen Dai ◽  
Wan‐Long Chuang ◽  
Jee‐Fu Huang ◽  
Ming‐Yen Hsieh ◽  
Ming‐Lung Yu
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Virological Response ◽  
Rapid Virological Response ◽  
Virus Genotype ◽  
Genotype 2

Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure

Hepatology ◽  
2008 ◽  
Vol 48 (2) ◽  
pp. 692-693
Author(s):  
Chia-Yen Dai ◽  
Wan-Long Chuang ◽  
Jee-Fu Huang ◽  
Ming-Yen Hsieh ◽  
Ming-Lung Yu
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virological Response ◽  
Rapid Virological Response ◽  
Genotype 1 ◽  
Virus Genotype

scholarly journals Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Alessio Aghemo ◽  
Elisabetta Degasperi ◽  
Maria Grazia Rumi ◽  
Enrico Galmozzi ◽  
Luca Valenti ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Treatment Failure ◽  
Virological Response ◽  
Hcv Rna ◽  
Rapid Virological Response ◽  
Virus Genotype ◽  
Viral Kinetics ◽  
Treatment Naïve ◽  
Baseline Predictor ◽  
The Impact

Background. The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients. The impact of baseline predictors of treatment outcome and their interplay with viral kinetics in HCV-1 CC patients has not been fully evaluated.Aim. To identify baseline and on-therapy predictors of treatment failure in HCV-1 IL28B CC patients.Methods. Treatment-naïve HCV-1 patients, compliant to PegIFN and Rbv who did not discontinue treatment for nonvirological reasons, were analyzed.Results. 109 HCV-1 IL28B CC were studied. Sixty were males, 39 with BMI >25, 69 with >600,000 IU/mL HCV RNA, 15 with HCV1a, and 30 with cirrhosis. Overall, 75 (69%) achieved an SVR; cirrhosis was the only baseline predictor of treatment failure (OR: 2.58, 95% CI: 1.07–6.21) as SVR rates were 53% in cirrhotics versus 75% in noncirrhotics (P=0.03). HCV RNA undetectability (<50 IU/mL) at week 4 (RVR) was achieved by 58 patients (53%). The SVR rates were independent of RVR in noncirrhotics, 76% (34/45) RVR (+) and 74% (25/34) RVR (−) (P=0.9). In cirrhotic patients, SVR rates were significantly higher in RVR (+) compared to RVR (−) (10/13 (77%) versus 6/17 (35%)P=0.03).Conclusions. In HCV-1 IL28B CC patients, cirrhosis is the only clinical baseline predictor of PegIFN and Rbv treatment failure. However, in IL28B CC cirrhotics, the achievement of RVR identifies those patients who still have high rates of SVR to Peg-IFN/Rbv therapy.

scholarly journals Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Hepatology ◽  
2007 ◽  
Vol 47 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Olav Dalgard ◽  
Kristian Bjøro ◽  
Helmer Ring-Larsen ◽  
Einar Bjornsson ◽  
Mona Holberg-Petersen ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virological Response ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Rapid Virological Response ◽  
Virus Genotype ◽  
Genotype 2 ◽  
Pegylated Interferon Alfa
Sign in / Sign up

Export Citation Format

Share Document